Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRRJ0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,785
Award facts
- Contract value 100% obligated
- $22,784.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,784.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. The delivery order, issued on December 18, 2025, is for Xolair 300 mg/2 ml syringes and represents a single-award delivery order with an ultimate completion date of January 12, 2026. This award includes no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform the work at its facility in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to supply comprehensive pharmaceutical products and medical consumables to Department of Defense military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month extension periods. DMS Pharmaceutical Group's established performance on numerous delivery orders across diverse pharmaceutical categories, including biologics and specialty medications, positions the company as a critical supplier within the federal military medical system's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FRRJ0?
SPE2DR26FRRJ0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FRRJ0 worth?
The government has obligated $22,785 on SPE2DR26FRRJ0.
Is contract SPE2DR26FRRJ0 an order under another contract?
Yes. SPE2DR26FRRJ0 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRJ0 competed?
The extent of competition for SPE2DR26FRRJ0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award